Tartrate-resistant acid phosphatase activity determined by enzyme immunoassay was higher in the serum of cancer patients than that in normal blood donors. The highest activity was found among patients having malignancy metastatic to bone. The classic colorimetric method showed a broad range of values among normal blood donors, and the contrast between normal and cancer patients was less obvious. Most of the cancer patients had normal to low alkaline phosphatase activities. The clinical significance of acid phosphatase for the diagnosis of prostatic cancer is well known. Extensive efforts from many laboratories have been directed toward establishing a specific analytical method for prostatic acid phosphatase. The study by Abul-Fadl and King (1) concerning inhibitor specificity of acid phosphatase among different tissues led to the recommendation of using the tartratesensitive fraction of acid phosphatase in serum for diagnosis of prostatic cancer (2). The clinical significance of the tartrate-resistant fraction on the other hand, is often neglected; indeed, the commercial immunochemical kits currently available have eliminated completely the measurement of the tartrate-resistant acid phosphatase.
The clinical significance of acid phosphatase for the diagnosis of prostatic cancer is well known. Extensive efforts from many laboratories have been directed toward establishing a specific analytical method for prostatic acid phosphatase. The study by Abul-Fadl and King (1) concerning inhibitor specificity of acid phosphatase among different tissues led to the recommendation of using the tartratesensitive fraction of acid phosphatase in serum for diagnosis of prostatic cancer (2). The clinical significance of the tartrate-resistant fraction on the other hand, is often neglected; indeed, the commercial immunochemical kits currently available have eliminated completely the measurement of the tartrate-resistant acid phosphatase.
In our experience, both tartrate-resistant and tartratesensitive fractions are increased in some prostatic cancer patients, although the tartrate-sensitive fraction is usually increased much more than the tartrate-resistant fraction. Our previous reports described the high activity of tartrateresistant acid phosphatase in the serum of normal children during physiological bone growth (3, 4) and in adults with osteolytic lesions due to malignancy metastatic to bone (3-
5).
The increase in tartrate-resistant acid phosphatase among patients with Gaucher's disease (6) (7) (8) and dengue fever (9) is also dependent on bone involvement.
In evaluating an enzyme immunoassay procedure (10) we developed recently for the analysis of acid phosphatase band in serum, we have studied the variation of tartrateresistant acid phosphatase among cancer patients. The data obtained were compared with those by a colorimetric method involving p-nitrophenyl phosphate as substrate. We also compared our results with the patients' activities of alkaline phosphatase, which is well-known to be related to osteoblastic activity (11). 
Materials and Methods
The colorimetric method and enzyme immunoassay procedure were described previously (10). Alkaline phosphatase was determined with reagent kits supplied by Sigma Chemical Co., St.Louis, MO.
Serum All diagnoses of malignancy had been histologically confirmed. Metastatic disease was evaluated by observation during surgery, results of standard automated determinations of blood analytes, and radiographic studies including ordinary roentgenograins and radionuclide scans of bone, liver, and brain, as well as computerized axial tomographic scanning.
The blood samples from cancer patients were collected with blood for other routine blood tests. After clotting and centrifugation, the serum was removed and stored at -70 #{176}C until analysis.
The samples were divided into four groups: group 1, from normal adult blood donors; group 2, from cancer patients without known metastases; group 3, from patients with cancer cells metastatic to lymph nodes or other tissues without involvement of the bone; and group 4, from patients with cancer cells metastatic to bone. Prostatic cancer patients were distributed between groups 2 and 4, there being no prostatic cancer patient with metastatic disease to soft tssues without bone involvement (group 3).
Results
The activity of tartrate-resistant acid phosphatase as determined by the enzyme immunoassay (Table 1) was increased in patients with malignancy, with and without metastatic disease. The highest values were observed in the patients with metastases to bone (group 4), but tartrateresistant acid phosphatase was also increased in patients with metastatic disease to nodes and other tissues than in patients with no known metastases. Eighty-five percent of group 4 had values above the normal range, compared with 44% of group 3 ( Figure 1) .
As determined by the colorimetric method, activities of tartrate-resistant acid phosphatase were similar among groups 1,2, and 3, but was increased in group 4 ( Table 1 ). As Figure 1 shows, most of the data in groups 2, 3, and 4 were within the normal range, with only 30% of the values for group 4 outside the normal range.
Most of the cancer patients had low alkaline phosphatase activity in their serum. Several samples in groups 2 and 4 had below-normal alkaline phosphatase activity ( .
In ( Figure 1 ). Only four samples in group 4 had very high values of alkaline phosphatase, and of these only one had a high activity of tartrate-resistant acid phosphatase. There was no correlation of alkali phosphatase activity to tartrateresistant acid phosphatase activity.
Discussion
The present data confirmed previous observations of high activities of tartrate-resistant acid phosphatase among cancer patients with cancer cellsmetastasized to bone, and showed that the immunochemical assay indicates this more satisfactorily than the colorimetricmethod.
The enzyme immunoassay produced lower values of tartrate-resistant acid phosphatase in serum of normal adults and higher values in cancer patients than did the colorimetnc method; as a result, the difference between the two groups of subjects is more obvious, presumably because of the higher specificity of the enzyme immunoassay method.
The major tartrate-resistant acid phosphatase in serum is osteoclastic acid phosphatase band Sb and erythrocytic phosphatase. The proportion of the latter is quite variable, depending on the extent of hemolysis of the sample. Precipitation of band 5b from the serum by a specific antibody, as in the enzyme immunoassay, eliminated the variable contributions from erythrocytic acid phosphatase so that the values for tartrate-resistant acid phosphatase in normal adults were lower and fell within a narrower range than the data obtained by the colorimetric method.
Among cancer patients, on the other hand, the tartrateresistant acid phosphatase released from osteoclasts may be partially inactivated during storage. Our previous data (10)
showed that inactivated purified acid phosphatase band 5b was reactivated by precipitation of the enzyme with the antibody. Therefore, the serum from cancer patients gave higher values by the enzyme immunoassay than by the colonimetric method. We would thus expect the enzyme immunoassay to give lower values for normal serum, where contamination by erythrocytic phosphatase is relatively high compared with the amount of isoenzyme band 5, and higher values in cancer patients, where erythrocytic phosphatase contamination is less than the amount of inactivated osteoclastic phosphatase.
Some of the "nonmetastatic" cancer patients (group 2) could have a small number of cancer cells in bone, which would be difficult to detect by bone scan. Among different types of cancer, bone involvement is seen most often among breast cancer and prostatic cancer, and the increase in tartrate-resistant acid phosphatase in the group 2 samples was, in fact, higher among patients with breast cancer or prostatic cancer than other cancer patients.
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All of the cancer patients were being treated at the time of sampling, but the exact clinical status of each was not available. The low activity of tartrate-resistant acid phosphatase in some patients may have been due to a good response to treatment. We will consider the tartrate-resistant acid phosphatase activity of individual patients at different stages of treatment in future studies.
Alkaline phosphatase is an enzyme marker of osteoblastic activity (11, 12); most of the cancer patients in this study, however, did not have increased serum activities of alkaline phosphatase. The few instances of extremely high activities of alkaline phosphatase, but normal tartrate-resistant acid phosphatase, could be due to damage of tissues other than bone.
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